Literature DB >> 35391656

Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p/MCL1.

Ying Zhao1, Yi Lan2, Yugang Chi3, Boping Yang3, Chunyan Ren3.   

Abstract

Chemoresistance is a common problem in cancer treatment, and circular RNA (circRNA) has been found to be associated with the progression of chemoresistance in cancer. However, the role and mechanism of circRNA centrosomal protein 128 (circ-CEP128) in the chemoresistance of cervical cancer (CC) are still unclear. The expression of circ-CEP128, microRNA (miR)-432-5p, and myeloid cell leukemia-1 (MCL1) was measured by quantitative real-time PCR. The paclitaxel resistance of cells was assessed using MTT assay. Cell proliferation, apoptosis, migration, and invasion were determined using MTT assay, colony formation assay, flow cytometry, and transwell assay. The protein levels of metastasis markers and MCL1 were examined using western blot analysis. Mice xenograft models were constructed to assess the effect of circ-CEP128 silencing on CC tumor growth and paclitaxel sensitivity. The interaction between miR-432-5p and circ-CEP128 or MCL1 was confirmed by dual-luciferase reporter assay and RIP assay. Circ-CEP128 had highly expression in CC tumor tissues and cells. Silencing of circ-CEP128 could enhance the paclitaxel sensitivity of CC cells by decreasing cell growth, migration, and invasion. Also, knockdown of circ-CEP123 reduced CC tumor growth and promoted the paclitaxel sensitivity of CC tumors. MiR-432-5p was found to be sponged by circ-CEP128, and its inhibitor could reverse the promoting function of circ-CEP128 silencing on the paclitaxel sensitivity of CC cells. Additionally, MCL1 was a target of miR-432-5p, and circ-CEP128 could sponge miR-432-5p to regulate MCL1. Besides, overexpressed MCL1 also could reverse the enhancing effect of miR-432-5p on the paclitaxel sensitivity of CC cells. In conclusion, the present study showed that circ-CEP128 silencing could increase the paclitaxel sensitivity of CC by regulating the miR-432-5p/MCL1 axis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cervical cancer; Circ-CEP128; MCL1; miR-432-5p

Year:  2022        PMID: 35391656     DOI: 10.1007/s10528-022-10201-y

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  35 in total

1.  circMTO1 promotes tumorigenesis and chemoresistance of cervical cancer via regulating miR-6893.

Authors:  Mengmeng Chen; Guihai Ai; Jianhong Zhou; Weipu Mao; Huan Li; Jing Guo
Journal:  Biomed Pharmacother       Date:  2019-06-18       Impact factor: 6.529

Review 2.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

3.  Management of cleft palate cases using a modified dunn procedure with skin graft to vomer flaps.

Authors:  S Stenström; B Thilander
Journal:  Scand J Plast Reconstr Surg       Date:  1974

4.  Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen.

Authors:  K Fujise; D Zhang; J Liu; E T Yeh
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

5.  Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047.

Authors:  Jing Guo; Mengmeng Chen; Guihai Ai; Weipu Mao; Huan Li; Jianhong Zhou
Journal:  Biomed Pharmacother       Date:  2019-05-10       Impact factor: 6.529

Review 6.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis.

Authors:  R W Craig
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

Review 7.  Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer.

Authors:  Bing Chen; Shenglin Huang
Journal:  Cancer Lett       Date:  2018-01-09       Impact factor: 8.679

8.  MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression.

Authors:  Z Fan; H Cui; H Yu; Q Ji; L Kang; B Han; J Wang; Q Dong; Y Li; Z Yan; X Yan; X Zhang; Z Lin; Y Hu; S Jiao
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

9.  Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.

Authors:  A Marijne Heeren; Iske F van Luijk; Joost Lakeman; Noëlle Pocorni; Jeroen Kole; Renée X de Menezes; Gemma G Kenter; Tjalling Bosse; Cornelis D de Kroon; Ekaterina S Jordanova
Journal:  Cancer Immunol Immunother       Date:  2019-10-15       Impact factor: 6.968

10.  Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.

Authors:  Florence Baettig; Tatjana Vlajnic; Marcus Vetter; Katharina Glatz; Jürgen Hench; Stephan Frank; Michel Bihl; Roberto Lopez; Michael Dobbie; Viola Heinzelmann-Schwarz; Céline Montavon
Journal:  J Immunother Cancer       Date:  2019-10-31       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.